Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD)

Interested in this Trial?

Contact Us

Trial Status Completed

Trial Identifier

NCT01037309

Condition

Duchenne Muscular Dystrophy

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

The purpose of this study is to see whether PRO044 is safe and effective to use as medication for DMD patients with a mutation around location 44 in the DNA for the dystrophin protein.

Eligibility Criteria

Birth Sex

Male

Age

5 Years to 16 Years

Healthy Volunteers

No

Drug/Treatment:

PRO044 SC, PRO044 IV

Phase:

Phase 1/Phase 2

Study Type:

Interventional

Number of Participants:

18

Study Started:

2009-12

Study Updated:

2018-10-16

Trial Locations

  • UZ Leuven

    Leuven, , Belgium

  • S.Anna Hospital

    Ferrara, , Italy

  • Leiden University Medical Center

    Leiden, , Netherlands

  • The Queen Silvia Children's Hospital

    Gothenburg, , Sweden

Inclusion Criteria

1. Boys aged between 5 and 16 years inclusive.
2. Duchenne muscular dystrophy resulting from a mutation correctable by treatment with PRO044.
3. Life expectancy of at least 6 months.
4. No previous treatment with investigational medicinal treatment within 6 months prior to the start of the (pre)-screening for the study.
5. No previous treatment with idebenone within 6 months prior to the start of the (pre)-screening for the study.
6. Willing and able to adhere to the study visit schedule and other protocol requirements.
7. Written informed consent signed (by parent(s)/legal guardian and/or the patient, according to the local regulations).
8. Glucocorticosteroids use which is stable for at least 2 months prior first drug administration.

Exclusion Criteria

1. Aberrant RNA splicing and/or aberrant response to PRO044, detected by in vitro PRO044 assay during pre-screening.
2. Known presence of dystrophin in ≥ 5% of fibers in a pre-study diagnostic muscle biopsy.
3. Severe muscle abnormalities defined as increased signal intensity in >50% of the tibialis anterior muscle at MRI.
4. FEV1 and/or FVC < 60% of predicted. 5. Current or history of liver or renal disease. 6. Acute illness within 4 weeks prior to treatment (Day 1) which may interfere with the measurements. 7. Severe mental retardation which in the opinion of the investigator prohibits participation in this study. 8. Severe cardiac myopathy which in the opinion of the investigator prohibits participation in this study. 9. Need for mechanical ventilation. 10. Creatinine concentration above 1.5 times the upper limit of normal (age corrected). 11. Serum ASAT and/or ALAT concentration(s) which suggest hepatic impairment. 12. Use of anticoagulants, antithrombotics or antiplatelet agents. 13. Use of idebenone. 14. Use of any investigational product within 6 months prior to the start of the (pre)-screening for the study. 15. Subject has donated blood less than 90 days before the start of the (pre)-screening for the study. 16. Current or history of drug and/or alcohol abuse. 17. Participation in another trial with an investigational product

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form